AbbVie (ABBV) Total Debt (2012 - 2026)
AbbVie (ABBV) posted quarterly Total Debt of $64.5 billion for Q1 2026, down 5.51% year-over-year from $68.3 billion in Q1 2025, and down 0.72% quarter-over-quarter from $65.0 billion in Q4 2025.
AbbVie (ABBV) Total Debt (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Total Debt for 15 consecutive years, with $64.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt fell 5.51% year-over-year to $64.5 billion; the TTM figure through Mar 2026 stood at $64.5 billion (down 5.51% YoY), while the FY2025 annual figure was $65.0 billion, up 7.72% from the prior year.
- Total Debt eased to $64.5 billion in Q1 2026 per ABBV's latest filing, from $65.0 billion in the prior quarter.
- Across five years, Total Debt topped out at $74.0 billion in Q1 2024 and bottomed at $55.8 billion in Q2 2023.
- Historically, Total Debt has averaged $65.2 billion across 5 years, with a median of $65.0 billion in 2025.
- On a YoY basis, Total Debt climbed as much as 6750.0% in 2022 and fell as far as 25.7% in 2022.
- AbbVie's Total Debt stood at $63.3 billion in 2022, then declined by 6.14% to $59.4 billion in 2023, then advanced by 1.61% to $60.3 billion in 2024, then increased by 7.72% to $65.0 billion in 2025, then slipped by 0.72% to $64.5 billion in 2026.
- Business Quant data shows ABBV's Total Debt at $64.5 billion in Q1 2026, $65.0 billion in Q4 2025, and $65.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 49.04 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 70.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 53.91 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 29.49 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 62.75 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 28.66 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 63.19 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.96 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 25.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.82 Bn |
| Mar 31, 2026 | 64.53 Bn |
| Dec 31, 2025 | 65.00 Bn |
| Sep 30, 2025 | 64.95 Bn |
| Jun 30, 2025 | 64.96 Bn |
| Mar 31, 2025 | 68.30 Bn |
| Dec 31, 2024 | 60.34 Bn |
| Sep 30, 2024 | 71.08 Bn |
| Jun 30, 2024 | 70.63 Bn |
| Mar 31, 2024 | 74.00 Bn |
| Dec 31, 2023 | 59.39 Bn |
| Sep 30, 2023 | 60.74 Bn |
| Jun 30, 2023 | 55.81 Bn |
| Mar 31, 2023 | 62.09 Bn |
| Dec 31, 2022 | 63.27 Bn |
| Sep 30, 2022 | 69.60 Bn |
| Jun 30, 2022 | 61.02 Bn |
| Mar 31, 2022 | 73.46 Bn |
| Dec 31, 2021 | 64.20 Bn |
| Sep 30, 2021 | 1.02 Bn |